Pliant Therapeutics, Inc. (NASDAQ:PLRX - Get Free Report)'s share price dropped 5.4% during trading on Monday . The stock traded as low as $14.34 and last traded at $14.38. Approximately 314,201 shares were traded during trading, a decline of 31% from the average daily volume of 455,462 shares. The stock had previously closed at $15.20.
Wall Street Analysts Forecast Growth
A number of analysts have weighed in on the company. Needham & Company LLC reaffirmed a "buy" rating and issued a $38.00 price target on shares of Pliant Therapeutics in a research report on Thursday, August 8th. Leerink Partners started coverage on Pliant Therapeutics in a report on Monday, September 9th. They issued an "outperform" rating and a $33.00 target price for the company. Leerink Partnrs raised Pliant Therapeutics to a "strong-buy" rating in a research report on Monday, September 9th. HC Wainwright reissued a "buy" rating and issued a $38.00 price target on shares of Pliant Therapeutics in a research report on Friday, September 13th. Finally, Oppenheimer reduced their price objective on shares of Pliant Therapeutics from $48.00 to $45.00 and set an "outperform" rating for the company in a research note on Thursday, August 8th. Eight research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Pliant Therapeutics presently has an average rating of "Buy" and a consensus target price of $40.57.
Get Our Latest Analysis on PLRX
Pliant Therapeutics Trading Down 3.6 %
The company has a debt-to-equity ratio of 0.08, a current ratio of 14.47 and a quick ratio of 14.47. The company has a market capitalization of $891.33 million, a price-to-earnings ratio of -4.74 and a beta of 1.13. The business has a fifty day moving average price of $12.59 and a 200 day moving average price of $12.62.
Pliant Therapeutics (NASDAQ:PLRX - Get Free Report) last issued its quarterly earnings results on Wednesday, August 7th. The company reported ($0.92) earnings per share for the quarter, missing analysts' consensus estimates of ($0.85) by ($0.07). On average, equities analysts expect that Pliant Therapeutics, Inc. will post -3.71 EPS for the current fiscal year.
Institutional Investors Weigh In On Pliant Therapeutics
Institutional investors have recently added to or reduced their stakes in the company. Capital International Investors raised its holdings in Pliant Therapeutics by 50.9% in the 1st quarter. Capital International Investors now owns 1,377,327 shares of the company's stock valued at $20,522,000 after acquiring an additional 464,860 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Pliant Therapeutics by 13.5% in the first quarter. Vanguard Group Inc. now owns 3,478,355 shares of the company's stock valued at $51,827,000 after purchasing an additional 412,486 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its position in Pliant Therapeutics by 4.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 3,959,088 shares of the company's stock worth $58,991,000 after purchasing an additional 173,172 shares during the period. Rice Hall James & Associates LLC acquired a new stake in Pliant Therapeutics during the second quarter worth $1,372,000. Finally, Renaissance Technologies LLC boosted its stake in Pliant Therapeutics by 233.8% during the second quarter. Renaissance Technologies LLC now owns 253,369 shares of the company's stock worth $2,724,000 after buying an additional 177,469 shares in the last quarter. 97.30% of the stock is owned by institutional investors and hedge funds.
About Pliant Therapeutics
(
Get Free Report)
Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis.
See Also
Before you consider Pliant Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pliant Therapeutics wasn't on the list.
While Pliant Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
